| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.088 | 0.6 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.6 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.6 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |